CLINICAL FACTORS PREDISPOSING TO ACHIEVEMENT OF RBC TRANSFUSION INDEPENDENCEIN LENALIDOMIDE-TREATED PATIENTS WITH LOW/INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES) WITHOUT DEL(5q) IN MDS-005 STUDY
MDS-005 STUDY: EFFECT OF BASELINE ENDOGENOUS ERYTHROPOIETIN ON RBC TRANSFUSION INDEPENDENCE IN LENALIDOMIDE-TREATED PATIENTS WITH LOW OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES WITHOUT DEL(5Q)
A PHASE 3 STUDY OF LENALIDOMIDE VERSUS PLACEBO IN RBC TRANSFUSION-DEPENDENT (TD) PATIENTS WITH LOWER-RISK MDS WITHOUT DEL(5Q) UNRESPONSIVE OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)